Pharma Mar, S.A. Reports Earnings Results for the First Quarter Ended March 31, 2021
May 04, 2021
Share
Pharma Mar, S.A. Announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced total revenue was EUR 51.261 million compared to EUR 99.453 million a year ago. Operating income was EUR 18.106 million compared to EUR 70.500 million a year ago. Net income was EUR 24.181 million compared to EUR 70.572 million a year ago.
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Companyâs product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
PHARMA MAR, S.A. 
